(3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine methanesulfonate

Catalog No. :
ACUKLU529
CAS No. :
217797-14-3
Molecular Formula :
C20H24FNO6S
Molecular Weight :
425.48

IUPAC Name:(3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine methanesulfonate

(3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine methanesulfonate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine methanesulfonate
IUPAC Name(3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine methanesulfonate
Molecular FormulaC20H24FNO6S
Molecular Weight425.48
SMILESCS(=O)(=O)O.FC1=CC=C([C@@H]2CCNC[C@H]2COC2=CC3=C(C=C2)OCO3)C=C1
InChI KeySHIJTGJXUHTGGZ-RVXRQPKJSA-N
SynonymCarboxiamidotriazol | PAROXETINE MESILATE [WHO-DD] | (3S,4R)-3-((Benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine methanesulfonate | 5,6beta-epoxy-cholesterol | M711N184JE | Paroxetine mesylate (USAN) | CHEBI:32181 | CCG-268946 | PIPERIDIN
CAS No.217797-14-3
PubChem CID9845306

Synthetic Route by SureRoute

1. ACUKLU529 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACUKLU529 route product structure diagram
    ACUKLU529217797-14-3
Inquiry

2. ACUKLU529 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACWVNQ372 route compound structure diagram
    ACWVNQ37261869-08-7 In Stock
  2. Plus
  3. ACAWBD401 route compound structure diagram
    ACAWBD4017774-34-7 In Stock
  4. Plus
  5. reactant_3 route compound structure diagram
    --
  6. Then
  7. ACUKLU529 route product structure diagram
    ACUKLU529217797-14-3
Inquiry

Comments (0)